FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2238672356> ?p ?o ?g. }

• W2238672356 endingPage "8" @default.
• W2238672356 startingPage "31" @default.
• W2238672356 abstract "The treatment of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD) is one of actual problems of modern gastroenterology and coloproctology. In recent years a great attention is paid to the molecules of adhesion. Adhesion proteins play a significant role in the development of inflammation in patients with IBD. They cause the migration of cells from the capillaries into the center of inflammation, i.e. do much to increase the inflammatory infiltration of the mucosa and homing of lymphocytes. Changes in the levels of adhesion factors under the influence of biological therapy have been insufficiently studied. So the aim of our study was to determine the diagnostic value of adhesion molecules--integrin-sVCAM-1 and selectins P-, E-, L- for the assessment of the effectiveness of therapy in patients with UC and CD and prognosis of the disease. 15 patients with IBD were examined (15 patients with Crohn's disease (CD)). 9 patients were treated using infliximab 5 mg/kg according to the standard scheme (0-2-6 and then every 8 weeks). 3 patients with IBD received anti-inflammatory therapy with the introduction of the culture of MSC in the number of 150 x 108 cells suspended in 200 ml of physiological solution with the addition of heparin (10 IU/ml). 3 patients received azathioprine (2 mg/kg) and glucocorticosteroids (GCS) 1 mg/kg. The clinical symptoms, the level of leukocytes, erythrocyte sedimentation rate, C-reactive protein and also were analyzed before and after the treatment with infliximab and transplantation of MSC. The status of the colonic mucosa was evaluated using colonoscopy with biopsy. The concentration of adhesion molecules L-selectin, E-selectin, P-selectin, integrin-sVCAM-1 in blood serum was analyzed using immunoenzyme method twice before the beginning of treatment and after 2 months. It is established that after the standard therapy with the use of corticosteroids and azathioprine clinical and laboratory signs of IBD activity and increased levels of adhesion molecules remained in all patients. It is reliably determined that under the influence of infliximab the levels of P-selectin, E-selectin and integrin-sVCAM-1 decrease to 8.9 +/- 1.0 ng/ml, 5.5 +/- 1.7 ng/ml, 9.5 +/- 4.4 ng/ml, respectively (p < 0.001) in all patients with IBD. This point to the suppression of the synthesis of the main inflammatory cytokine alpha-TNF. Transplantation of MSC causes significant decrease of P-selectin, E-selectin to 6.9 +/- 1.1 ng/ml and 5.7 +/- 1.3 ng/ml, respectively (p < 0.001). Integrin-sVCAM-1 has decreased slightly to 12.2 +/- 2.2 ng/ml, p > 0.1. This is associated with the onset of the maximum therapeutic effect only in 1-2 months after transplantation. The levels of P-selectin, E-selectin, integrin-sVCAM-1, reflecting the acute phase of inflammation, decreased after MSC transplantation and infliximab induction therapy. The level of L-selectin, reflecting a chronic autoimmune inflammation, practically does not decrease after the MSC transplantation (8.9 +/- 0.5 ng/ml, p < 0.05) and infliximab induction therapy (9.6 +/- 0.8 ng/ml, p > 0.1). These include the appointment of long-term infliximab therapy and repeated MSC transplantations. P-selectin, E-selectin, L-selectin, integrin-sVCAM-1 are modern markers of inflammation and may be used to assess the effectiveness of standard and biological therapy in patients with IBD, and to predict the course of the disease." @default.
• W2238672356 created "2016-06-24" @default.
• W2238672356 creator A5010064281 @default.
• W2238672356 creator A5020594963 @default.
• W2238672356 creator A5026817065 @default.
• W2238672356 creator A5029181894 @default.
• W2238672356 creator A5033967567 @default.
• W2238672356 creator A5046762408 @default.
• W2238672356 creator A5053857539 @default.
• W2238672356 creator A5080563136 @default.
• W2238672356 date "2013-01-01" @default.
• W2238672356 modified "2023-09-23" @default.
• W2238672356 title "[Cell adhesion molecules in evaluation of Crohn's disease therapy]." @default.
• W2238672356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24294769" @default.
• W2238672356 hasPublicationYear "2013" @default.
• W2238672356 type Work @default.
• W2238672356 sameAs 2238672356 @default.
• W2238672356 citedByCount "3" @default.
• W2238672356 countsByYear W22386723562015 @default.
• W2238672356 crossrefType "journal-article" @default.
• W2238672356 hasAuthorship W2238672356A5010064281 @default.
• W2238672356 hasAuthorship W2238672356A5020594963 @default.
• W2238672356 hasAuthorship W2238672356A5026817065 @default.
• W2238672356 hasAuthorship W2238672356A5029181894 @default.
• W2238672356 hasAuthorship W2238672356A5033967567 @default.
• W2238672356 hasAuthorship W2238672356A5046762408 @default.
• W2238672356 hasAuthorship W2238672356A5053857539 @default.
• W2238672356 hasAuthorship W2238672356A5080563136 @default.
• W2238672356 hasConcept C126322002 @default.
• W2238672356 hasConcept C155619193 @default.
• W2238672356 hasConcept C16224149 @default.
• W2238672356 hasConcept C203014093 @default.
• W2238672356 hasConcept C2776760755 @default.
• W2238672356 hasConcept C2776914184 @default.
• W2238672356 hasConcept C2777138892 @default.
• W2238672356 hasConcept C2778143017 @default.
• W2238672356 hasConcept C2778260677 @default.
• W2238672356 hasConcept C2779134260 @default.
• W2238672356 hasConcept C2779280984 @default.
• W2238672356 hasConcept C2780479503 @default.
• W2238672356 hasConcept C71924100 @default.
• W2238672356 hasConcept C90924648 @default.
• W2238672356 hasConceptScore W2238672356C126322002 @default.
• W2238672356 hasConceptScore W2238672356C155619193 @default.
• W2238672356 hasConceptScore W2238672356C16224149 @default.
• W2238672356 hasConceptScore W2238672356C203014093 @default.
• W2238672356 hasConceptScore W2238672356C2776760755 @default.
• W2238672356 hasConceptScore W2238672356C2776914184 @default.
• W2238672356 hasConceptScore W2238672356C2777138892 @default.
• W2238672356 hasConceptScore W2238672356C2778143017 @default.
• W2238672356 hasConceptScore W2238672356C2778260677 @default.
• W2238672356 hasConceptScore W2238672356C2779134260 @default.
• W2238672356 hasConceptScore W2238672356C2779280984 @default.
• W2238672356 hasConceptScore W2238672356C2780479503 @default.
• W2238672356 hasConceptScore W2238672356C71924100 @default.
• W2238672356 hasConceptScore W2238672356C90924648 @default.
• W2238672356 hasIssue "3" @default.
• W2238672356 hasLocation W22386723561 @default.
• W2238672356 hasOpenAccess W2238672356 @default.
• W2238672356 hasPrimaryLocation W22386723561 @default.
• W2238672356 hasRelatedWork W2026261284 @default.
• W2238672356 hasRelatedWork W2032766004 @default.
• W2238672356 hasRelatedWork W2238672356 @default.
• W2238672356 hasRelatedWork W2312256768 @default.
• W2238672356 hasRelatedWork W2397385543 @default.
• W2238672356 hasRelatedWork W2405823598 @default.
• W2238672356 hasRelatedWork W2413996451 @default.
• W2238672356 hasRelatedWork W3032508331 @default.
• W2238672356 hasRelatedWork W1581389539 @default.
• W2238672356 hasRelatedWork W2030593178 @default.
• W2238672356 isParatext "false" @default.
• W2238672356 isRetracted "false" @default.
• W2238672356 magId "2238672356" @default.
• W2238672356 workType "article" @default.